Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
NL0012044747
Tue, 01.08.2023
Redcare Pharmacy N.V.
Redcare Pharmacy Q2 2023: While fast sales growth continues unabated at 46%, adj. EBITDA margin improved 5.3pp year over year to 3.2%. Company raises full-year guidance.
Total sales up 46% in Q2 to EUR 420M and by 34% in H1 to EUR 792M.
Excluding MediService AG (consolidated since mid-May), sales up 25% in Q2 and 24% in H1.
Non-Rx growth 27% in [ … ]
Thu, 06.07.2023
Redcare Pharmacy N.V.
Very successful quarter for Redcare Pharmacy N.V. with a further acceleration in sales growth.
Total sales growth 47% to EUR 421M in Q2.
Year to date sales EUR 793M, a growth of 34%.
Excluding the sales of MediService AG (transaction with Galenica AG completed mid-May), sales growth was 26% to EUR 361M in Q2 and 24% to EUR 733M year to date, dri [ … ]
Thu, 06.07.2023
Redcare Pharmacy N.V.
Very successful quarter for Redcare Pharmacy N.V. with a further acceleration in sales growth.
Total sales growth 47% to EUR 421M in Q2.
Year to date sales EUR 793M, a growth of 34%.
Excluding the sales of MediService AG (transaction with Galenica AG completed mid-May), sales growth was 26% to EUR 361M in Q2 and 24% to EUR 733M year to date, dri [ … ]
Tue, 13.06.2023
Redcare Pharmacy N.V.
Sevenum, the Netherlands, 13 June 2023. As part of its rebranding, Europe’s leadinge-pharmacy changed its ticker symbol on the stock exchange from SAE to RDC. Following this, and the simultaneous launch of the new corporate website, the corporate rebranding is now official.
With today’s event, Europe’s largest one-stop pharmacy takes another step [ … ]
Tue, 13.06.2023
Redcare Pharmacy N.V.
Sevenum, the Netherlands, 13 June 2023. As part of its rebranding, Europe’s leadinge-pharmacy changed its ticker symbol on the stock exchange from SAE to RDC. Following this, and the simultaneous launch of the new corporate website, the corporate rebranding is now official.
With today’s event, Europe’s largest one-stop pharmacy takes another step [ … ]
Tue, 06.06.2023
Redcare Pharmacy N.V.
SHOP APOTHEKE EUROPE PROMOTED TO THE MDAX.
Sevenum, the Netherlands, 6 June 2023. SHOP APOTHEKE EUROPE will be promoted to the MDAX, the leading German stock index for mid-sized companies, following the latest index review by global index provider STOXX Ltd.
Effective 19 June 2023, SHOP APOTHEKE EUROPE will be among the 50 largest listed companie [ … ]
Tue, 06.06.2023
Redcare Pharmacy N.V.
SHOP APOTHEKE EUROPE PROMOTED TO THE MDAX.
Sevenum, the Netherlands, 6 June 2023. SHOP APOTHEKE EUROPE will be promoted to the MDAX, the leading German stock index for mid-sized companies, following the latest index review by global index provider STOXX Ltd.
Effective 19 June 2023, SHOP APOTHEKE EUROPE will be among the 50 largest listed companie [ … ]
Thu, 11.05.2023
SHOP APOTHEKE EUROPE N.V.
Joint Venture Approved: SHOP APOTHEKE EUROPE and Galenica Create the Leading Online Pharmacy in Switzerland.
Sevenum, the Netherlands, 11 May 2023. The competition authorities in Switzerland and Austria confirmed the approval for the joint venture between SHOP APOTHEKE EUROPE and Galenica today.
In late March 2023, SHOP APOTHEKE EUROPE, Europe’s [ … ]
Thu, 11.05.2023
SHOP APOTHEKE EUROPE N.V.
Joint Venture Approved: SHOP APOTHEKE EUROPE and Galenica Create the Leading Online Pharmacy in Switzerland.
Sevenum, the Netherlands, 11 May 2023. The competition authorities in Switzerland and Austria confirmed the approval for the joint venture between SHOP APOTHEKE EUROPE and Galenica today.
In late March 2023, SHOP APOTHEKE EUROPE, Europe’s [ … ]
Tue, 02.05.2023
SHOP APOTHEKE EUROPE N.V.
SHOP APOTHEKE EUROPE: STRONG Q1 WITH 22% SALES GROWTH AND EBITDA MARGIN IN UPPER PART OF FULL-YEAR GUIDANCE.
Total sales up 22% to EUR 372 million.
Non-Rx sales growth 23%; outpacing the full-year guidance of 10 to 20%.
Adj. EBITDA margin 2.4%, 3.8 pp better than Q1 2022; upper part of the full-year guidance of 0.5 to 2.5%.
Comfortably on tra [ … ]